Table 2.
Malignancy exposure-adjusted event rates (12-week results)
| Placebo (n = 879; 195 PY) |
Ustekinumab (n = 613; 140 PY) |
Brodalumab 210 mg Q2W (n = 1496; 336 PY) |
All brodalumab (n = 3066; 688 PY)a |
|
|---|---|---|---|---|
| Adjudicated malignancies | 0 | 1 (0.7) | 2 (0.6) | 4 (0.6) |
| NMSC | 0 | 0 | 1 (0.3) | 3 (0.4) |
| Basal cell carcinoma | 0 | 0 | 0 | 2 (0.3) |
| Squamous cell carcinoma | 0 | 0 | 1 (0.3) | 1 (0.1) |
| SEER-adjudicated malignancies | 0 | 1 (0.7) | 1 (0.3) | 1 (0.1) |
| Penile squamous cell carcinoma | 0 | 0 | 1 (0.3) | 1 (0.1) |
| Prostate cancer | 0 | 1 (0.7) | 0 | 0 |
Values are the number of events (exposure-adjusted event rate per 100 patient-years [n/PY × 100])
NMSC nonmelanoma skin cancer, PY total patient-years of exposure through week 12, Q2W every 2 weeks, SEER Surveillance, Epidemiology, and End Results
aThe all-brodalumab group includes all patients who received ≥ 1 dose of brodalumab